NEW YORK – Indivumed said on Wednesday that it has launched an international collaborative called the Oncology Alliance for Individualized Medicine to advance precision cancer treatments through the company's multi-omics database IndivuType.
The alliance includes leading cancer clinics and research institutions with molecular oncology expertise across Brazil, Germany, Italy, Ireland, Japan, Korea, Singapore, Spain, Sweden, UK, and US. The specific members of the alliance were not named in a statement announcing its launch.
Hamburg, Germany-based Indivumed's database IndivuType combines genomic, transcriptomic, proteomic, immuno-phenotype, and digital histopathology data with clinical information from cancer patients to enable research. It also features bioinformatic and AI tools for data analysis. The company hopes to use this platform to enable precision cancer drug discovery.
In 2018, the company collaborated with the Agency for Science, Technology and Research in Singapore to launch a cancer library initiative to collect a variety of omics data from consenting individuals to build out IndivuType's repository.Â
Last year, it partnered with Evotec on precision drug discovery for colorectal cancer and non-small cell lung cancer.
The alliance seeks to use the datasets available within IndivuType and create specific research projects in which investigators use real-world clinical care data to improve understanding of cancers and advance novel treatment strategies. The group expects to publish the first findings from this alliance in the coming months, according to a statement from Indivumed.
The group is also supporting the creation of an educational program called Precision Oncology Web Education Resource (POWER) with Georgetown University and Oxford University.